An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus

A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 1 or Type 2 Diabetes Mellitus in Macedonia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01542424

Enrollment

1889

Registered

2012-03-02

Start date

2006-03-31

Completion date

2006-12-31

Last updated

2017-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

Brief summary

This trial is conducted in Europe. The aim of this trial is to investigate efficacy and safety of NovoMix® 30 (biphasic insulin aspart 30) or Levemir® (insulin detemir) in subjects with type 1 or 2 diabetes mellitus.

Interventions

DRUGbiphasic insulin aspart 30

Prescribed at the discretion of the physician

DRUGinsulin detemir

Prescribed at the discretion of the physician

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Macedonian people with diabetes mellitus (Type 1 or Type 2)

Design outcomes

Primary

Measure	Time frame
HbA1c (glycosylated haemoglobin)	—

Secondary

Measure	Time frame
Percentage of subjects reaching HbA1c target of maximum 7.0%	—
Postprandial plasma glucose (PPG)	—
Fasting plasma glucose (FPG)	—
Change in body weight	—
Incidence of adverse events	—

Countries

North Macedonia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026